Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Capital Expenditures for 9 consecutive years, with $70000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 3400.0% to $70000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $291000.0 through Dec 2025, up 781.82% year-over-year, with the annual reading at $291000.0 for FY2025, 781.82% up from the prior year.
  • Capital Expenditures for Q4 2025 was $70000.0 at Akebia Therapeutics, down from $77000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $126000.0 in Q2 2025, with the low at $2000.0 in Q3 2024.
  • Average Capital Expenditures over 4 years is $55222.2, with a median of $59000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures soared 93.22% in 2022, then surged 3750.0% in 2025.
  • Over 4 years, Capital Expenditures stood at $59000.0 in 2021, then skyrocketed by 93.22% to $114000.0 in 2022, then crashed by 98.25% to $2000.0 in 2024, then skyrocketed by 3400.0% to $70000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $70000.0, $77000.0, and $126000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.